Clinical Trial Results: A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication [Phase 1]

View source ↗

Summary

Phase 1 trial assessing tolerability and efficacy signals of varying doses of BI 1569912 in adults with depressive disorders already on antidepressants.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Depressive Disorder
• Major Depressive Disorder

Drugs mentioned

• BI 1569912

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Depressive Disorder, Major | Phase 1 | Status: COMPLETED | Results posted: 2026-08-14